ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update
ImageneBio $30 Million Private Placement Ignites Stock
ImageneBio Announces $30 Million Private Placement
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
ImageneBio to Participate in Leerink Global Healthcare Conference
BML Capital Management LLC Makes New Investment in ImageneBio, Inc. $IMA
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences
ImageneBio, Inc. (NASDAQ:IMA) Short Interest Update
Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals
Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals
Ikena Oncology (IKNA) Moves to Buy: Rationale Behind the Upgrade
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
Ikena Oncology Reports Third Quarter 2024 Financial Results
Ikena Oncology Reports Second Quarter 2024 Financial Results
Best Momentum Stocks to Buy for July 12th
New Strong Buy Stocks for July 12th
UPDATE – Ikena Oncology Announces Strategic Update
Ikena Oncology Announces Strategic Update
Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference
Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
Down -29.05% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround
Down -33.01% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround
Ikena Oncology Outlines Key Priorities and Provides Corporate Updates
Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results
Ikena Oncology to Present at Multiple November 2023 Investor Conferences
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Ikena Oncology Inc. (NASDAQ: IKNA)
Ikena Oncology to Participate in September 2023 Investor Conferences
Ikena Oncology, Inc. (IKNA) Reports Q2 Loss, Lags Revenue Estimates
Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
Recent Price Trend in Ikena Oncology, Inc. (IKNA) is Your Friend, Here's Why
Ikena Oncology, Inc. (IKNA) Is a Great Choice for 'Trend' Investors, Here's Why
Ikena Oncology to Participate in Upcoming Investor Conferences
Ikena Oncology, Inc. (IKNA) Reports Q1 Loss, Tops Revenue Estimates
Ikena Oncology, Inc. (IKNA) Stock Jumps 7.9%: Will It Continue to Soar?
Ikena Oncology, Inc. (IKNA) Reports Q4 Loss, Tops Revenue Estimates
Ikena Oncology, Inc. (IKNA) Reports Q3 Loss, Tops Revenue Estimates
Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Ikena Oncology to Participate in Spring 2022 Investor Conferences